Based on our results showing that tumor-intrinsic YTHDF1 contributes to immune evasion and is associated with ICI resistance, we explored whether YTHDF1 deficiency improves the efficacy of ICI therapy in mouse models. The gene discussed is YTHDF1; the disease is neoplasm.